ImmuPharma plc (LON:IMM – Get Free Report)’s share price traded down 8.9% during mid-day trading on Thursday . The company traded as low as GBX 3.33 and last traded at GBX 3.33. 1,838,091 shares traded hands during mid-day trading, a decline of 36% from the average daily volume of 2,850,241 shares. The stock had previously closed at GBX 3.65.
ImmuPharma Price Performance
The stock has a market cap of £20.78 million, a P/E ratio of -9.00 and a beta of 3.00. The business’s fifty day moving average price is GBX 4.31 and its 200 day moving average price is GBX 5.61.
ImmuPharma (LON:IMM – Get Free Report) last announced its quarterly earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 1,397.44%. On average, analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
